Physician profile
Benjamin Leach
NPI 1497026140
$13,629.61
in general payments reported to CMS, 2019-2025
31 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $2,160 · 2021: $2,455 · 2022: $2,005 · 2023: $536 · 2024: $5,467 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,895 · Food and Beverage: $1,277 · Education: $47.05 · Travel and Lodging: $17.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,895.00 |
| Food and Beverage | $1,277.25 |
| Education | $47.05 |
| Travel and Lodging | $17.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,304.56 | 2020-2024 | Lynparza |
| Novartis Pharmaceuticals Corporation | $3,556.22 | 2019-2022 | |
| Genzyme Corporation | $3,530.91 | 2019-2024 | |
| Beigene USA, INC. | $220.41 | 2022-2023 | Brukinsa |
| Glaxosmithkline, LLC. | $215.16 | 2021-2023 | Zejula |
| Pfizer INC. | $214.92 | 2019-2025 | |
| Kite Pharma, INC. | $196.71 | 2024-2025 | Yescarta |
| Boston Scientific Corporation | $156.37 | 2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $151.67 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $144.07 | 2023 | |
| Genentech USA, INC. | $124.61 | 2019-2020 | |
| Immunogen, INC. | $86.51 | 2024 | Elahere |
| Array Biopharma INC | $80.51 | 2019 | |
| Merck Sharp & Dohme LLC | $66.13 | 2020-2021 | |
| Janssen Biotech, INC. | $57.92 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $56.39 | 2024 | |
| Amgen INC. | $53.53 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $51.20 | 2019 | |
| Gilead Sciences, INC. | $46.27 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.40 | 2019-2024 | Fruzaqla |
| Seagen INC. | $37.52 | 2019-2020 | |
| Incyte Corporation | $36.31 | 2019-2020 | |
| Sirtex Medical INC | $28.18 | 2019 | |
| Foundation Medicine, INC. | $26.97 | 2019 | |
| Eisai INC. | $24.45 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $24.20 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.35 | 2020 | |
| Clovis Oncology, INC. | $20.73 | 2019 | |
| Puma Biotechnology, INC. | $19.14 | 2019 | |
| Btg International INC. | $17.29 | 2019 | |
| Celgene Corporation | $17.00 | 2024 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Leach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.